News

Zacks Investment Research on MSN2h
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
Forecasting The Future: 7 Analyst Projections For Eli Lilly
Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...
Eli Lilly files lawsuits over other companies selling Zepbound and Mounjaro
INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.
24/7 Wall St. on MSN10d
Visa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?
Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...